SEGMENTED INFORMATION (Tables)

3 Months Ended

Mar. 31, 2024

SEGMENTED INFORMATION

Schedule of Segmented Revenue and Net Profit/(Loss)

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2024
REVENUE	$	3,165		$	2,378,686		$	-		$	2,381,851
COST OF REVENUE		(2,252	)		(2,014,568	)		-			(2,016,820	)
GROSS PROFIT		913			364,118			-			365,031
OTHER INCOME		38,694			163,153			-			201,847
OPERATING EXPENSES
General and administrative		(80,855	)		(415,629	)		(149,422	)		(645,906	)
(LOSS)/PROFIT FROM OPERATIONS		(41,248	)		111,642			(149,422	)		(79,028	)
FINANCE COSTS		(1,950	)		(2,687	)		(24	)		(4,661	)
(LOSS)/PROFIT BEFORE TAX		(43,198	)		108,955			(149,446	)		(83,689	)
Tax expense		-			(20,068	)		-			(20,068	)
NET (LOSS)/PROFIT	$	(43,198	))	$	88,887		$	(149,446	)	$	(103,757	)

	MRNA Scientific Malaysia			Chemrex			BGLC			Total
	Three months ended March 31, 2023
REVENUE	$	7,436		$	2,369,769		$	-		$	2,377,205
COST OF REVENUE		(5,347	)		(2,002,961	)		-			(2,008,308	)
GROSS /PROFIT		2,089			366,808			-			368,897
OTHER INCOME		1,126			116,218			-			117,344
OPERATING EXPENSES
General and administrative		(46,255	)		(383,177	)		(107,440	)		(536,872	)
(LOSS)/PROFIT FROM OPERATIONS		(43,040	)		99,849			(107,440	)		(50,631	)
FINANCE COSTS		(666	)		(1,779	)		-			(2,445	)
(LOSS)/PROFIT BEFORE TAX		(43,706	)		98,070			(107,440	)		(53,076	)
Tax expense		-			(15,990	)		-			(15,990	)
NET (LOSS)/PROFIT	$	(43,706	)	$	82,080		$	(107,440	)	$	(69,066	)

	As of March 31, 2024 and December 31, 2023
	Total Assets				Total Liabilities
	2024		2023		2024		2023
BGLC & MRNA Scientific	$	4,535,139	$	4,723,449	$	330,827	$	260,119
Chemrex		6,626,344		6,676,344		1,486,469		1,481,822
TOTAL		11,161,483		11,399,793		1,817,296		1,741,941